XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide‐induced murine sepsis. Issue 15 (11th August 2017)

• Record Type: Journal Article
• Authors: Damarla, Mahendra; Johnston, Laura F.; Liu, Gigi; Gao, Li; Wang, Lan; Varela, Lidenys; Kolb, Todd M.; Kim, Bo S.; Damico, Rachel L.; Hassoun, Paul M.
• Is Part Of: Physiological reports. Volume 5:Issue 15(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-08-11
• Subjects: Febuxostat -- lipopolysaccharide -- mortality -- organ dysfunction -- oxidative damage -- sepsis -- xanthine oxidoreductase; Physiology -- Periodicals; 571
• DOI: 10.14814/phy2.13377
• Languages: English
• ISSNs: 2051-817X

Abstract

Abstract: Sepsis is a leading cause of death among patients in the intensive care unit, resulting from multi‐organ failure. Activity of xanthine oxidoreductase (XOR), a reactive oxygen species (ROS) producing enzyme, is known to be elevated in nonsurvivors of sepsis compared to survivors. We have previously demonstrated that XOR is critical for ventilator‐induced lung injury. Using febuxostat, a novel nonpurine inhibitor of XOR, we sought to determine the role of XOR inhibition in a murine model of sepsis‐induced lung injury and mortality. C57BL/6J mice were subjected to intravenous (IV) lipopolysaccharide (LPS) for various time points, and lungs were harvested for analyses. Subsets of mice were treated with febuxostat, pre or post LPS exposure, or vehicle. Separate groups of mice were followed up for mortality after LPS exposure. After 24 hr of IV LPS, mice exhibited an increase in XOR activity in lung tissue and a significant increase in pulmonary endothelial barrier disruption. Pretreatment of animals with febuxostat before exposure to LPS, or treatment 4 h after LPS, resulted in complete abrogation of XOR activity. Inhibition of XOR with febuxostat did not prevent LPS‐induced pulmonary vascular permeability at 24 h, however, it accelerated recovery of the pulmonary endothelial barrier integrity in response to LPS exposure. Furthermore, treatment with febuxostat resulted in significant reduction in mortality. Inhibition of XOR with febuxostat accelerates recovery of the pulmonary endothelial barrier and prevents LPS‐induced mortality, whether given before or after exposure to LPS. Abstract : Xanthine oxidase inhibition with febuxostat does not prevent pulmonary vascular permeability but rather accelerates recovery of the endothelial barrier integrity. Further, xanthine oxidase inhibition with febuxostat improves survival following lipopolysaccharide‐induced murine sepsis.